US Patent

US9029533 — Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors

Method of Use · Assigned to Ariad Pharmaceuticals Inc · Expires 2026-12-22 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds of a specific formula and their preparation and use as kinase inhibitors.

USPTO Abstract

This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

Drugs covered by this patent

ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1283`	—	ponatinib-hydrochloride
`U-1701`	—	ponatinib-hydrochloride
`U-1700`	—	ponatinib-hydrochloride
`U-1701`	—	ponatinib-hydrochloride

Patent Metadata

Patent number: US9029533
Jurisdiction: US
Classification: Method of Use
Expires: 2026-12-22
Drug substance claim: No
Drug product claim: No
Assignee: Ariad Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.